In vitro anti-tumour and cyto-selective effects of coumarin-3-carboxylic acid and three of its hydroxylated derivatives, along with their silver-based complexes, using human epithelial carcinoma cell lines

Cancer Letters

Volumn 248, Issue 2, 2007, Pages 321-331

  Thati, Bhumika ^a   Noble, Andy ^a   Creaven, Bernadette S ^a   Walsh, Maureen ^a   McCann, Malachy ^a,b   Kavanagh, Kevin ^a,b   Devereux, Michael ^a   Egan, Denise A ^a  

^a DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

chemotherapeutic potential; Coumarin 3 carboxylic acid; Cyto selectivity; Hydroxylated coumarin 3 carboxylic acid derivatives; Silver complexes

Indexed keywords

6 HYDROXYCOUMARIN 3 CARBOXYLATOSILVER; 6 HYDROXYCOUMARIN 3 CARBOXYLIC ACID; 7 HYDROXYCOUMARIN 3 CARBOXYLATOSILVER; 7 HYDROXYCOUMARIN 3 CARBOXYLIC ACID; 8 HYDROXYCOUMARIN 3 CARBOXYLATOSILVER; 8 HYDROXYCOUMARIN 3 CARBOXYLIC ACID; CARBOXYLIC ACID DERIVATIVE; COUMARIN 3 CARBOXYLIC ACID; SILVER DERIVATIVE; UNCLASSIFIED DRUG;

AMES TEST; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CYTOTOXICITY; DNA SYNTHESIS; DRUG ACTIVITY; HUMAN; HUMAN CELL; HYDROXYLATION; IC 50; KIDNEY CELL; LIVER CELL; MUTAGENESIS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; COUMARINS; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; INHIBITORY CONCENTRATION 50; MUTAGENICITY TESTS; SILVER COMPOUNDS;

EID: 33847261546     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.08.009     Document Type: Article

References (37)

1. Fricker P.S. Metal compounds in cancer therapy. The Role of Metals in Cancer Therapy (1994), Chapman and Hall, London, UK 10-15
2. Marzano C., Trevisan A., Giovagnini L., and Fregonal D. Synthesis of a new platinum(II) complex: anticancer activity and nephrotoxicity in vitro. Toxicol. In Vitro 16 (2002) 413-419
3. Murray R.D., Mendez J., and Brown S.A. The Natural Coumarins: Occurrence, Chemistry and Biochemistry (1982), John Wiley & Sons, UK pp. 1-12
4. Egan D.A., O'Kennedy R., Moran E., and Thornes R.D. The pharmacology, metabolism, analysis and applications of coumarin and coumarin related compounds. Drug Metab. Rev. 22 (1990) 503-529
5. Kolodziej H., Kayser O., Woerdenbag H.J., Van Ulden W., and Pras N. Structure-cytotoxicity relationships of a series of natural and semi-synthetic simple coumarins as assessed in two human tumour cell lines. Naturforchung 52 (1997) 240-244
6. Jimenez-Orozco F.A., Molina-Guarneros J.A., Mendoza-Patino N., Leon-Cedeno F., Flores-Perez B., Santos-Santos E., and Mandoki J.J. Cytostatic activity of coumarin metabolites and derivatives in the B-16-F10 murine melanoma cell line. Melanoma Res. 9 (1999) 243-247
7. Finn G.J., Creaven B.S., and Egan D.A. Study of the in vitro cytotoxic potential of natural and synthetic coumarin derivatives using human normal and neoplastic skin cell lines. Melanoma Res. 11 (2001) 461-476
8. Laurin P., Klich M., Dupis-Hamelin C., Mauvais P., Lassaigne P., Bonnefoy A., and Musicki B. Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B. Bioorg. Med. Chem. Lett. 9 (1999) 2079-2084
9. Hoult R.J.S., and Paya M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen. Pharmacol. 27 (1996) 713-722
10. Pillai S.P., Menon S.R., Mitscher L.A., Pillai C.A., and Shankel D.A. Umbelliferone analogues and their potential to inhibit benzo[a]pyrene and hydrogen peroxide induced mutations. J. Nat. Prod. 62 (1999) 1358-1362
11. Kimura Y., Okuda H., Arichi S., Baba K., and Kozawa M. Inhibition of the formation of 5-hydroxy-6,8,11,14-eicosatetraenoic acid from arachidonic acid in polymorphonuclear leukocytes by various coumarins. Biochim. Biophys. Acta 834 (1985) 224-229
12. Hoffmanova J., Kozubik A., Dusek L., and Pachernik J. Inhibitors of lipoxygenase metabolism exert synergistic effects with retinoic acid on differentiation of human leukaemia HL-60 cells. Eur. J. Pharmacol. 350 (1998) 273-284
13. Maucher A., Kager M., and von Angerer E. Evaluation of the anti-tumour activity of coumarin in prostrate cancer models. J. Clin. Res. Clin. Oncol. 119 (1993) 150-154
14. Sharma S., Stutzman D., Kellof J.G., and Steele V.E. Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. Cancer Res. 54 (1994) 5848-5855
15. Egan D.A., James P., Cooke D., and O'Kennedy R. Studies on the cytostatic and cytotoxic effects and mode of action of 8-nitro-7-hydroxycoumarin. Cancer Lett. 118 (1997) 201-211
16. Hayes J.D., Pulford D.J., Ellis E.M., McLeod R., James R.F.L., Seidegard J., Mosialou E., Jernstrom B., and Neal G.E. Regulation of rat glutathione S-transferase A5 by cancer chemopreventative agents: mechanisms of inducible resistance to aflatoxin B1. Chem. Biol. Interact. 111 (1998) 51-67
17. Finn G.J., Creaven B.S., and Egan D.A. A study of the role of cell cycle events mediating the mechanism of action of coumarin derivatives in human malignant melanoma cells. Cancer Lett. 214 (2004) 43-54
18. Finn G.J., Creaven B.S., and Egan D.A. Daphnetin-induced differentiation of human renal carcinoma cells & its mediation by p38 mitogen-activated protein kinase. Biochem. Pharmacol. 67 (2004) 1779-1788
19. Finn G.J., Creaven B.S., and Egan D.A. Effects of coumarin derivatives on differentiation of melanotic melanoma cells: A functional role for mitogen-activated protein kinases. Eur. J. Pharm. Sci. 26 (2005) 16-25
20. Marshall M.E., Mendelshon L., Butler K., Wiseman C., Harvey J., and MacDonald S.J. Treatment of metastatic melanoma with coumarin and cimetidine. Am. Soc. Oncol. 5 (1986) 186
21. Marshall M.E., Ryles M., Butler K., and Weiss L. Treatment of advanced renal cell carcinoma (RCC) with coumarin and cimetidine: Long term follow-up of patients on a phase I trial. J. Cancer Res. Clin. Oncol. 120 (1994) 535-538
22. Kokotos G., Theodoru V., and Tzougraki C. Synthesis and in vitro cytotoxicity of aminocoumarin platinum(II) complexes. Bioorg. Med. Chem. Lett. 7 (1997) 2165-2168
23. Manalov I., Kostova I., Netzeva T., Konstantinova S., and Karaivanova M. Cytotoxic activity of cerium complexes with coumarin derivatives. Arch. Pharm. Med. Chem. 333 (2002) 93-98
24. Kostova I., Manalov I., and Karaivanova M. Synthesis, physiochemical characterisation and cytotoxic screening of new zirconium complexes with coumarin derivatives. Arch. Pharm. 334 4 (2001) 157-162
25. Creaven B.S., Egan D.A., Kavanagh K., McCann M., Noble A., Thati B., and Walsh M. Synthesis, characterization and antimicrobial activity of a series of substituted coumarin-3-carboxylatosilver(I) complexes. Inorg. Chim. Acta 359 (2006) 3976-3984
26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: applications to proliferation and cytotoxicity assays. J. Immunol. 65 (1983) 55-63
27. Portsmann T., Ternyck T., and Aveameas S. Quantitation of 5-bromo-2-deoxyuridine incorporation into an enzyme immunoassay for the assessment of the lymphoid proliferative response. J. Immunol. Meth. 82 (1985) 169-179
28. Lorcozio A., and Long B.H. Biochemical characterisation of elasamicin and other coumarin-related antitumour agents as potent inhibitors of human topoisomerase II. Eur. J. Cancer 29A 14 (1993) 1985-1991
29. Moran D.M., and Ames B.N. Revised methods for the Salmonella mutagenicity tests. Mutat. Res. 113 (1983) 173-215
30. Baul T.S., Rynajah W., Willem R., Beisemans M., Verbruggen I., Holeapek M., Vos D.D., and Linden A. Dibutyltin(IV) complexes of the 5-[(E)-2-(Aryl)-1-diazenyl]-2-hydroxybenzoic acid ligand: an investigation of the structures by X-ray diffraction, solution and solid state tin NMR, electrospray ionisation MS and assessment of in vitro cytoxicity. J. Inorg. Chem. 689 (2004) 4691-4701
31. Han I., Kin O.K., Lee G.Y., Sung Y.K., Song R., and Sohn Y.S. Enhanced antitumour activity of trans(±)-1,2-Diaminocyclo-hexaneglutamatoplatinum(II) formulated with stealth liposomes. Bioorg. Med. Chem. 11 (2003) 5443-5447
32. 4 display anti-cancer activity in human cancer cells, Chem. Biol. Interact, in press.
33. Hidalago E., and Dominguez C. Study of cytotoxic mechanisms of silver nitrate in human dermal fibroblasts. Toxicol. Lett. 98 (1997) 169-179
34. Waring M.J. Variations of the supercoils in closed circular DNA by binding of antibiotics and drugs: evidence for molecular models involving intercalation. J. Mol. Biol. 54 (1970) 247-279
35. Dougherty G. The unwinding of circular DNA by intercalating agents as determined by gel electrophoresis. Biosci. Rep. 3 (1983) 453-460
36. Heffeter P., Jakupec M.A., Korner W., Wild S., von Keyserlingk N., Elbling L., Zorbas H., Korynevska A., Knasmuller S., Sutterluty H., Micksche M., and Keppler B.K. Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III) trithiocyanate (KP772; FFC24). Biochem. Pharmacol. 71 (2006) 426-440
37. Cross H.J., Tilby M., Chipman J.K., Ferry D.R., and Gescher A. Effect of quercetin on the genotoxic potential of cisplatin. Int. J. Cancer 3 (1996) 404-408